With anifrolumab under review by regulatory authorities in the US, EU and Japan, AstraZeneca PLC has presented more positive data on the therapy which could become the first treatment approved for systemic lupus erythematosus (SLE) in over a decade.
The UK drugs major has presented a post-hoc analysis of pooled data from the TULIP Phase III trials at the...